A practical reference on phase 2 trial: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-14 and is reviewed periodically as new material appears.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Human evidence remains limited to controlled studies. A phase 2 trial in adults with obesity reported large, dose-dependent reductions in body weight over 48 weeks, with gastrointestinal events as the most frequently recorded adverse effect. Phase 3 programs designated TRIUMPH, for obesity, and TRANSCEND, for type 2 diabetes, are intended to confirm efficacy and to characterize safety in larger populations. Related studies are examining conditions such as knee osteoarthritis in people with obesity and metabolic liver disease. Open questions include long-term tolerability, effects on lean mass, and what happens after treatment is stopped.
Retatrutide is an investigational synthetic peptide that acts on three receptor targets at once: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon. It is developed by Eli Lilly and appears in the literature and in trial registries under the code LY3437943. The molecule belongs to a class of engineered peptides designed to resist rapid breakdown and permit infrequent subcutaneous administration. No regulatory agency has approved it for clinical use, and all available human data come from controlled trials rather than from routine practice.
The intended pharmacology combines three signals in one molecule. GLP-1 receptor activation reduces appetite and slows gastric emptying, effects already exploited by approved incretin-based therapies. GIP receptor engagement is associated with improved insulin sensitivity and with direct effects on adipose tissue, although how much it contributes to overall outcomes is still debated. Glucagon receptor agonism raises energy expenditure and supports hepatic lipid handling, a mechanism that also tends to increase glucose output. The triple profile is hypothesized to produce a larger metabolic effect than single or dual agonism, but the relative weight of each receptor in humans is not settled.
| Property | Value | Notes |
|---|---|---|
| Storage temperature (solid) | -20 °C or below | Freezer storage with desiccant |
| Solubility | Soluble in water and aqueous buffer | Careful dissolution needed at higher concentrations |
| Appearance | White to off-white lyophilised powder | Visual inspection for discolouration |
| Primary analytical method | Reversed-phase HPLC with UV detection | Paired with mass spectrometry for identity |
| Common synonyms | Triple-agonist peptide; GLP-1/GIP/glucagon agonist | Naming varies across the literature |
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
冻干粉通常在低温环境下保存，复溶之后需要按指定条件在较短时间内使用。反复冻融和剧烈振荡可能促进聚集，低吸附容器则能减少多肽在管壁上的损失。批号、日期与处理条件的完整记录，是后续复核与问题追溯的基础。
供应环节涉及来源核实与文件审核两类工作。分析证书、批次记录以及第三方检测报告构成常见的可追溯材料。来源不清的样品很难确认身份与纯度，因此核实步骤在实际操作中具有明确意义。缺少方法细节的报告通常无法复核。
Leslie Hicks is an American full professor of analytical chemistry at the University of North Carolina at Chapel Hill. Her work primarily focuses on the study of proteomics and protein post-translational modifications using mass spectrometry, and identifying biologically active peptides in plants.
== Bibliography == Prentice, B. E., & Benell, D. (1992). "Determinants of empty returns by US refrigerated trucks: conjoint analysis approach". Canadian Journal of Agricultural Economics/Revue canadienne d'agroeconomie, 40(1), 109-127. doi:10.1111/j.1744-7976.1992.tb03680.x (abstract).
=== Origin and Penfold directorship === CSL was founded in 1916 as Commonwealth Serum Laboratories, an Australian government body focused on vaccine manufacture. Under the first director, William Penfold, CSL commenced operation in the vacant Walter and Eliza Hall Institute building at the Royal Melbourne Hospital in 1918 before moving to its purpose-built Parkville premises in the following year.
United States Policies targeting Muslims: Since the implementation of added security measures in the aftermath of the 2001 World Trade Centre attacks, reports of discrimination against people perceived to be Muslim by American border security officers have been prevalent in the media. The travel restrictions implemented during the Trump presidency primarily against Muslim majority countries have provoked controversy over whether such measures are a legitimate Border security measure or unethically discriminatory. Separation of families seeking asylum: In April 2018, as part of its "zero tolerance" policy, the American government ordered the separation of the children of refugees and asylum seekers from their parents. As a consequence of popular outrage, and criticism from the medical and religious communities, the policy was put on hold by an executive order signed by Trump on 20 June 2018. Under the policy, federal authorities separated children from their parents, relatives, or other adults who accompanied them in crossing the border, whether apprehended during an illegal crossing or, in numerous reported cases, legally presenting themselves for asylum. The policy involved prosecuting all adults detained at the Mexican border, imprisoning parents, and handing minors to the American Department of Health and Human Services (Spanish: Departamento de Salud y Servicios Sociales de los Estados Unidos). The federal government reported that the policy resulted in the separation of over 2300 children from their parents.
polymerase Any of a class of enzymes which catalyze the synthesis of polymeric molecules, especially nucleic acid polymers, typically by encouraging the base pairing of free nucleotides with those of an existing complementary template strand. DNA polymerases and RNA polymerases are essential for DNA replication and transcription, respectively.
Sources: en.wikipedia.org
Subsequently, Antonescu assumed dictatorial powers and became President of the Council of Ministers, as the self-titled "Leader" of the state. In 1941, as an ally of Nazi Germany, Romania entered World War II by declaring war on the Soviet Union. A shift in fortunes only became discernible after the defeat at Stalingrad and the subsequent change of the USSR from a defensive to an offensive posture. On 23 August 1944, with the Soviet army having been present in northern Moldova since March, King Mihai I forcibly removed Marshal Ion Antonescu from power, as he refused to sign an armistice with the Allies of World War II. Following Antonescu's outright refusal, King Mihai I ordered the dismissal and arrest of the marshal, and Romania switched sides to join the Allies.
The state runs most public universities in Croatia. Students who perform well academically pay only administrative fees which are less than €100 per year. Students who fail multiple classes in a year must retake the courses and pay a partial or full tuition fee.
=== Toxins === Some cases of biliary atresia may result from exposure to aflatoxin B1, and to a lesser extent aflatoxin B2 during late pregnancy. Intact maternal detoxification protects baby during intrauterine life, yet after delivery, the baby struggles with the aflatoxin in its blood and liver. Moreover, the baby feeds aflatoxin M1 from its mom, as aflatoxin M1 is the detoxification product of aflatoxin B1. It is a milder toxin that causes cholangitis in the baby. There are isolated examples of biliary atresia in animals. For instance, lambs born to sheep grazing on land contaminated with a weed (Red Crumbweed) developed biliary atresia at certain times. The plants were later found to contain a toxin, now called biliatresone. Studies are ongoing to determine whether there is a link between human cases of biliary atresia and toxins such as biliatresone. There are some indications that a metabolite of certain human gut bacteria may be similar to biliatresone.
Counterfeit drugs are a serious problem. People can potentially ingest useless or dangerous drugs without their knowledge. Custom package seals, authentication labels, holograms, and security printing can be valued parts of an entire security system. They help verify that enclosed drugs are what the package says they are. Drug counterfeiters, however, often work with package counterfeiters, some of whom can be sophisticated. No packaging system is completely secure.
Sources: en.wikipedia.org
In February 2025, Good me held its initial public offering becoming a listed company on the Hong Kong Stock Exchange with the offering raising US$233 million. On its trading debut, its shares dropped 6.4%. The IPO elevated founder Wang Yun'an's personal stake to an estimated HK$8.6 billion (about US$1.2 billion).
This phase was initially supported by worker remittances from abroad and a sharp rise in exports of labour-intensive goods like textiles. Subsequently service and software exports accelerated as global communication costs fell. Overall, private business investment rose significantly as the Indian government shifted its economic priorities. By the mid-2010s, India's economy was rapidly growing. It led to gains in poverty reduction, increased national tax collection, and a surge in private investment. As the Indian government methodically withdrew from direct investment in industry, it simultaneously increased public spending on vital infrastructure projects to keep pace with accelerating urbanisation. This economic opening also diversified the domestic economy. New industries emerged, most notably in information technology services; the national judicial infrastructure slowly adapted. However, growth was accompanied by widening income gaps, with some data showing only limited gains in overall welfare and everyday quality of life. Moreover, rapid development has exerted accelerated pressure on the environment. In response, activist political movements emerged to resist environmental degradation.
On 16 January 2015, the company announced that they would acquire Trophos for €470 million ($543 million) in order to increase the company's neuromuscular disease presence. The deal will centre on the Phase II and III spinal muscular atrophy drug olesoxime (TRO19622). In April 2015, Roche acquired CAPP Medical, and its chief development of technology for cancer screening and monitoring via the detection of circulating tumour DNA. In August, the company announced its intention to acquire GeneWEAVE, Inc. for up to $425 million in order to strengthen its microbial diagnostics business. Days later the company acquired Kapa Biosystems, Inc. for $445M, focussing on next generation sequencing and polymerase chain reaction applications. In October 2015, the company acquired Adheron Therapeutics for $105 million (plus up to $475 million in milestone payments). In January 2016, the company announced it would acquire Tensha Therapeutics for $115 million upfront, with $420 million in contingent payments. In January 2017, the company acquired ForSight VISION4. In June, the company acquired the diabetes management platform, mySugr GmbH for an undisclosed price. In November Roche acquired Viewics, Inc. In late December the company announced it would acquire Ignyta Inc, expanding its global oncology business. In February 2018, Roche announced it would acquire Flatiron Health, a business specialising in US cancer data analytics, for $1.9 billion. In June of the same year the company announced it would acquire the outstanding shares of Foundation Medicine for $2.4 billion ($137 per share).
Multiple methods allow for the quantitation of proteins by mass spectrometry, and recent advances have enabled quantifying thousands of proteins in single cells. Protein quantification by mass spectrometry benefits from efficient sampling (counting) of many ions per protein compared to other methods. Quantifications can be performed by label-free methods and by multiplexed methods, which use isotopic mass tags as labels. Multiplexed methods can improve both quantitative accuracy and throughput. Typically, stable (e.g. non-radioactive) heavier isotopes of carbon (13C) or nitrogen (15N) are incorporated into one sample while the other one is labeled with corresponding light isotopes (e.g. 12C and 14N). The two samples are mixed before the analysis. Peptides derived from the different samples can be distinguished due to their mass difference. The ratio of their peak intensities corresponds to the relative abundance ratio of the peptides (and proteins). The first generation of methods for isotope labeling included SILAC (stable isotope labeling by amino acids in cell culture), trypsin-catalyzed 18O labeling, ICAT (isotope coded affinity tagging), and iTRAQ (isobaric tags for relative and absolute quantitation). The more recent generation of multiplexing methods include tandem mass tags (TMT) for DDA data and mTRAQ for multiplexed DIA (plexDIA). "Semi-quantitative" mass spectrometry can be performed without labeling of samples. Typically, this is done with MALDI analysis (in linear mode).
== Medical uses == Metribolone was never approved for medical use, a situation unlikely to change given its liver toxicity even at low doses. It was studied for the potential treatment of advanced breast cancer in women but development was abandoned.
Sources: en.wikipedia.org
Mass spectrometry provides the most direct confirmation of molecular mass. Reversed-phase chromatography adds a retention-time signature that supports identity when compared against a reference standard. No single method is sufficient on its own.
Cool, dry conditions with desiccant are standard for the solid form. Long-term storage is usually at freezer temperatures, with short-term handling at refrigerator temperature. Vials are allowed to equilibrate before opening to prevent condensation.
Lipid conjugation increases hydrophobicity, which shifts chromatographic retention and can broaden peaks. It also creates additional related species when acylation is incomplete or the chain is oxidised. Methods are therefore developed to separate acylated and non-acylated forms explicitly.
It is an investigational peptide that activates three hormone receptors: GIP, GLP-1 and glucagon. It is being studied mainly for obesity and type 2 diabetes, and it is not approved for any clinical use. Published information comes from controlled trials rather than from general practice.